ST. PAUL, Minn., Sept. 21 /PRNewswire/ -- Brennen Medical, LLC, a leader in biomaterials technology, announces the sale of its XenMatrix(R) device to Davol Inc., a subsidiary of C.R. Bard, Inc. The agreement provides Davol with the worldwide rights and related assets of the hernia products business of Brennen Medical, LLC. This acquisition includes technology for a non crosslinked xenograft device for use in soft tissue repair including hernia and abdominal wall reconstruction.
“We are extremely pleased with the successful clinical outcomes of XenMatrix. Now with the acquisition by C.R. Bard, this product will reach a far greater number of patients worldwide, who will truly benefit from this device,” said Phillip Lawin, PhD, President of Brennen Medical.
XenMatrix and DermMatrix are trademarks and/or registered trademarks of C. R. Bard, Inc. or an affiliate.
SOURCE Brennen Medical, LLC
CONTACT: Phillip Lawin, PhD, of Brennen Medical, LLC, 1-800-328-9105,
BrennenMedical@att.net
Web site: http://www.brennenmed.com/
